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Abbreviations
and Acronyms
CO = cardiac output
Ea = effective arterial
elastance
EDV = end-diastolic volume
Ees = end-systolic elastance
EF = ejection fraction
ESPVR = end-systolic
pressure–volume
relationship
HF = heart failure
HR = heart rate
LV = left ventricular
LVOT = left ventricular
outﬂow tract
MAP = mean arterial
pressure
Pes = end-systolic pressure
PP = pulse pressure
PV = pressure-volume
SV = stroke volume
TAC = total arterial
compliance
TPR = total peripheral
resistance
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1978maximally reduced (3). These
beneﬁts were associated with
left ventricular (LV) remodeling
toward normal (5).
In experimental studies, HR
reduction improves cardiac efﬁ-
ciency (6) and diastolic ﬁlling
by prolonging diastole (7). Cur-
rently, it is unknown whether
chronic HR reduction in humans
also can reduce total afterload.
Interestingly, the effective arterial
elastance (Ea), integrating the
mean and pulsatile load on the
heart, directly depends on HR
and total peripheral resistance
(TPR) (8,9). Therefore, HR re-
ductionmay be directly associated
with LV unloading (10). Fur-
thermore, in animal models,
ivabradine improves aortic di-
stensibility by reducing vascular
ﬁbrosis and oxidative stress, result-
ing in improved ventricular-arterial
interaction (10). Therefore, we hy-
pothesized that isolated HR
reduction with ivabradine reduces
Ea by increasing vascular compli-ance, thereby unloading the left ventricle by improv-
ed ventricular-arterial interaction. This hypothesis was tested
using data obtained from the subpopulation of the SHIFT
(Systolic Heart Failure Treatment With the If Inhibitor
Ivabradine Trial) who participated in the pre-speciﬁed
echocardiographic substudy previously reported (5).Figure 1 Scheme of a PV Diagram of the Left Ventricle
The blue squarelike ﬁgure represents a pressure-volume (PV) diagram of the left
ventricle. Effective arterial elastance (Ea) is calculated by the end-systolic pressure
(Pes) divided by stroke volume (SV) and represents the slope of the blue line
connecting the end-systolic pressure volume point (Pes, ESV) and end-diastolic
volume (EDV) on the x-axis. Ea represents both mean and pulsatile load to which
the left ventricle is exposed. Total arterial compliance (TAC) is calculated by the
ratio of SV divided by pulse pressure (PP ¼ Psystolic-Pdiastolic). TAC is a parameter of
ventricular pulsatile load. The red line shows the ESPVR, which is mainly charac-
terized by its slope Ees, a measure of cardiac contractility. It is calculated by the
ratio of Pes and the ESV, referred to as the Sunagawa calculation. Ventricular-
arterial coupling is deﬁned by the coupling ratio of Ea/Ees. EF ¼ ejection fraction;
HR ¼ heart rate; TPR ¼ total peripheral resistance.Methods
Study design. The design of the SHIFT was described
in detail previously (2,3,11). Brieﬂy, this randomized,
double-blind, placebo-controlled, parallel-group, multina-
tional clinical trial evaluated 6,505 male or female patients
with moderate to severe chronic HF and documented LV
systolic dysfunction (LV ejection fraction [EF] 35%).
Eligible patients were in sinus rhythm with a resting HR
of 70 beats/min on 12-lead electrocardiography; they had
been clinically stable for 4 weeks and had been admitted
to the hospital for worsening HF within the previous
12 months. HR and blood pressure were measured twice at
5-min intervals at 2 consecutive visits 2 weeks apart. All
participants were receiving guidelines-based background
therapy for HF, including maximized beta-blocker therapy,
if tolerated. Other inclusion and exclusion criteria have
been described previously (2,3,11). After a 2-week run-in
period, patients were randomly assigned to receive either
ivabradine (5 mg bid) or placebo. Randomization was
stratiﬁed according to the dose of beta-blocker intakeat randomization and country. At subsequent visits at
14 and 28 days and every 4 months thereafter (or at any
other time if necessary), the dose of blinded study
medication was increased to 7.5 mg bid or decreased to
2.5 mg bid depending on resting HR and tolerability.
The SHIFT echocardiography substudy was performed at
89 centers in 21 countries participating in the main
SHIFT. In total, the present analysis used 275 of the
411 patients of the SHIFT echocardiography substudy,
speciﬁcally excluding those in the substudy who did not
have both HR and stroke volume (SV) measured at the
time of both echocardiographic measurements. To avoid
selection bias, all the patients at each participating center
were invited to enter the substudy, and the included
patients signed a speciﬁc informed consent in addition to
the documents related to the main study. The main study
and substudy were approved by the local institutional
review board at all participating centers. The substudy
was carried out in accordance with the Declaration of
Helsinki (1964) and its text revisions. The SHIFT is
registered (ISRCTN70429960).
Deﬁnition of the Ea, total arterial compliance, and end-
systolic elastance. Ea is a measure of both mean and
pulsatile load, providing an integrated parameter reﬂecting
the net impact of arterial vascular load on the heart (Fig. 1).
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1979The index was introduced by Sunagawa et al. (12) in the
1980s and veriﬁed in humans by Kelly et al. (8). Ea is
calculated by the ratio of end-systolic pressure (Pes) (mmHg)
and SV (ml) (8) (Fig. 1). Graphically, Ea can be depicted as
the absolute value of the slope of a line linking the coordinate
points of end-systolic volume (ESV) and the end-diastolic
volume (EDV) (Fig. 1, red line). Ea is dependent on TPR
and HR as follows:
TPR can be deﬁned by the following equation:
TPR ¼ ðMAP CVPÞ=CO [1]
where MAP is the mean arterial pressure (mm Hg), CVP is
the central venous pressure (mm Hg), and CO is cardiac
output (l/min).
CO is deﬁned by:
CO ¼ SV HR [2]
Substituting Equation 2 in Equation 1 results in:
TPR ¼ ðMAP CVPÞ=ðSV HRÞ [3]
When assuming that CVP is stable and low compared with
MAP and MAP is approximately equal to the Pes, Equation
3 can be recalculated as:
TPRzPes=ðSV HRÞ; [4]where Pes ¼ 0.9  systolic blood pressure (mm Hg)
measured by arm cuff (13). The term can be rearranged to:
TPR HRzPes=SV [5]
Pes/SV is per deﬁnition the Ea. Hence, Ea is dependent on
HR and TPR.
The pulsatile load of the heart is deﬁned by total arterial
compliance (TAC) (Fig. 1). TAC is deﬁned as the ratio of
SV and pulse pressure (PP) (14): TAC ¼ SV/PP. PP is
calculated by the difference in systolic and diastolic pressure
measured by arm cuff.
LV end-systolic elastance (Ees) is the slope of the end-
systolic pressure-volume relationship ESPVR and repre-
sents LV contractility (12) (Fig. 1). Normally it can only be
calculated invasively by reducing the preload when using
a pressure-volume (PV) conductance catheter. However, it
can also be derived echocardiographically by single-beat
analysis. Two different methods for Ees calculation were
performed.
According to Sunagawa et al. (12) and Schwartzenberg
et al. (15), Ees can be calculated by the ratio of the Pes and
the end-systolic volume, assuming the x-axis intercept
of ESPVR V0 ¼ 0. The equation was used in experimental
studies (12) and in patients with HF (15) This formula
was calculated in 134 ivabradine-treated patients and
128 placebo-treated patients: Ees ¼ Pes/ESV.
According to Chen et al. (16), single-beat Ees can be
assessed using an algorithm containing systolic and diastolicblood pressure, SV, EF, and pre-ejection and total systolic
ejection time intervals from LV outﬂow Doppler. This
formula was also calculated in patients receiving placebo or
ivabradine treatment equipped with a complete dataset
(n ¼ 41 per group).
Ventricular-arterial interaction can be assessed by the ratio
Ea/Ees in the pressure volume diagram and is deﬁned as the
coupling ratio.
Echocardiographic imaging and blood pressure measurements.
Echocardiography was performed at baseline (in the 2 weeks
between selection and inclusion) and within 1 month of the 8-
month visit. Echocardiographic recordings were carried
out according to a pre-deﬁned operational protocol and
read blindly and centrally in the core laboratory at the
Montreal Heart Institute. The 2 recordings were to
be made by the same technician using the same technique
and the same equipment. Transthoracic echocardiography
was performed with a phased-array imaging system
equipped with a transducer with second harmonics
capability. Images were obtained in the parasternal long-
and short-axis and apical views, with the subject lying in
the left lateral position (for details, see Tardif et al. [5]).
To quantify SV, the LV outﬂow tract (LVOT) time
velocity integral was measured by pulsed-wave Doppler in
the apical 5-chamber view and LVOT diameter d was
measured in the parasternal long-axis view.
SV was assessed by ¼ LVOT time velocity integral
 ðd=2Þ2  3:14
Blood pressure was measured by an arm cuff system in
sitting position after a 5-min rest. LV EDV and EF were
measured by using the modiﬁed Simpson rule or Dumesnil
formula.
Statistics. Summary statistics are reported as mean (SD) for
continuous variables and as number (%) for categorical
variables. Differences between treatment groups at baseline
were analyzed using 2-sample t tests for continuous variables
and chi-square tests for categorical variables; p values from
these tests are reported. Associations between HR and the
hemodynamic parameters at baseline were also investigated.
For presentation purposes, the hemodynamic parameters
are presented by tertiles of HR; p values from analysis of
variance models for tests for trends are also reported.
Echocardiographic, blood pressure, and hemodynamic
parameters are summarized by treatment group at baseline
and month 8; the change from baseline (month 8 baseline)
values are also reported. Analysis of variance models
were used to test for differences between the treatment groups
at each time point (and change from baseline) and paired
t tests to test for differences within each group over time.
Associations between the EF and coupling ratio at base-
line and for the change from baseline were analyzed using
scatterplots and correlation coefﬁcients.
Values p < 0.05 were considered to reﬂect statistically
signiﬁcant differences. All analyses were carried out using
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1980SAS for Windows version 9.2 (SAS Institute, Cary, North
Carolina).Results
Of the 275 patients involved in this analysis, 143 were
treated with ivabradine and 132 with placebo. Table 1
summarizes the demographic and clinical data of both
groups at substudy entry. Patients from the 2 study arms did
not differ signiﬁcantly with respect to the listed parameters.
When the study population was subdivided into tertiles
of HR at baseline, TAC decreased with higher HR, whereas
Ea signiﬁcantly increased (Table 2, Fig. 2). PP and Pes
remained largely unchanged, whereas SV signiﬁcantly
decreased with increasing HR (Table 2). Increase in Ea and
reduction of TAC were mainly dependent on decreased SV.Table 1 Basic Characteristics of Both Groups at Baseline
All
(N ¼ 275)
Ivabradine
(n ¼ 143)
Placebo
(n ¼ 132) p Value
Demographic
characteristics
Age, yrs 59.7 (11.1) 60 (10.8) 59.4 (11.5) 0.65
Male 224 (81.5) 119 (83.2) 105 (79.5) 0.43
Clinical data
NYHA functional
class II
153 (55.6 ) 82 (57.3) 71 (53.8 0.55
NYHA functional
class IIIþIV
122 (44.4) 61 (42.7) 61 (46.2)
Heart rate,
beats/min
71 (11.4) 71 (11.8) 71 (11.0) 0.70
Systolic blood
pressure,
mm Hg
122 (15) 123 (15.7) 121 (14.2) 0.33
Diastolic blood
pressure,
mm Hg
76 (8.6) 76 (9.2) 76 (8.0) 0.81
Medical history
Current smoker 45 (16.4) 29 (20.3) 16 (12.1) 0.07
Diabetes 85 (30.9) 42 (29.4) 43 (32.6) 0.57
Hyperlipidemia 39 (14.2) 23 (16.1) 16 (12.1) 0.35
CAD 197 (71.6) 105 (73.4) 92 (69.7) 0.49
Previous MI 165 (60.0) 90 (62.9) 75 (56.8) 0.30
Coronary artery
surgery
42 (15.3) 22 (15.4) 20 (15.2) 0.95
Stroke 23 (8.4) 13 (9.1) 10 (7.6) 0.65
Drugs
Diuretics 238 (86.5) 126 (88.1) 112 (84.8) 0.43
Beta-blocker 257 (93.5) 135 (94.4) 122 (92.4) 0.51
ACE inhibitor 216 (78.5) 114 (79.7) 102 (77.3) 0.62
ARB 42 (15.3) 24 (16.8) 18 (13.6) 0.47
Lipid-lowering
agents
190 (69.1) 99 (69.2) 91 (68.9) 0.96
Cardiac
glycosides
56 (20.4) 28 (19.6) 28 (21.2) 0.74
Renal function
Creatinine,
mmol/l
98 (23.2) 99 (25.5) 97 (20.4) 0.44
Values are mean (SD) or n (%).
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker; CAD ¼ coronary
artery disease; MI ¼ myocardial infarction; NYHA ¼ New York Heart Association.Pes and PP remained relatively unchanged as HR increased
(Table 2).
The effect of isolated HR reduction on LV hemody-
namics and ventricular-arterial coupling at baseline and after
8 months of ivabradine treatment is summarized in Table 3.
At baseline, heart rate hemodynamic and coupling param-
eters did not differ signiﬁcantly between the ivabradine and
placebo groups. Accordingly, EDV was similar in both
groups (Table 3).
After 8 months, ivabradine-treated patients showed
a signiﬁcantly decreased HR compared with controls. PP,
MAP, and Pes in the placebo and ivabradine groups did
not differ signiﬁcantly (Table 3). HR reduction was
accompanied by a signiﬁcant increase in SV in the ivabra-
dine group. This change was associated with a signiﬁcant
increase in TAC and a decrease in Ea compared with
placebo. TPR did not differ between both groups. LV EDV
was signiﬁcantly reduced in the ivabradine group after 8
months of treatment compared with baseline (leftward shift
of the PV loop) (Table 3) but showed no signiﬁcant
difference compared with placebo. Nevertheless, both the
relative and absolute reductions of EDV were signiﬁcantly
increased compared with placebo. Additionally, Ees,
describing LV contractility, showed no signiﬁcant difference
in the ivabradine or placebo group based on both calcula-
tions (Table 3). The coupling ratio Ea/Ees, representing
vascular-ventricular interaction, was similar at baseline in
the 2 groups. After 8 months, the Ea/Ees ratio decreased
signiﬁcantly in the ivabradine group (p < 0.01) (Table 3)
and compared with the placebo group (p < 0.001). Addi-
tionally, a strong inverse correlation between EF and the
coupling ratio Ea/Ees (r ¼ 0.77, p < 0.001) (Fig. 3)
as well as the change in coupling ratio and change in EF in
the ivabradine-treated patients (r ¼ 0.63, p < 0.001) and
placebo-treated patients (r ¼ 0.61, p < 0.001) could be
detected. Notably, there was no signiﬁcant correlation
between Ea and Ees at baseline (r ¼ 0.07, p ¼ 0.22).Table 2
Heart Rate Subdivided in Tertiles and
Hemodynamic Parameters at Baseline
Hemodynamics
1st Tertile
HR <65
beats/min
(n ¼ 93)
2nd Tertile
65  HR 75
beats/min
(n ¼ 91)
3rd Tertile
HR >75
beats/min
(n ¼ 91) p Value*
Pes, mm Hg 110  13 109  13 111  14 0.55
Pulse pressure,
mm Hg
48  12 45  11 46  12 0.31
Stroke volume,
ml
64  14 60  16 53  15 <0.001
Total arterial
compliance,
ml/mm Hg
1.5  0.6 1.4  0.5 1.2  0.4 <0.001
Effective
arterial
elastance,
mm Hg/ml
1.8  0.5 1.9  0.5 2.3  0.7 <0.001
Values are mean  SD. *p value from tests for trend.
0.0
0.5
1.0
1.5
2.0
2.5
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
Total arterial compliance  
Effective arterial elastance  
p < 0.001 for trend 
p < 0.001 for trend 
<65 bpm 65 ≤ HR ≤ 75 bpm >75 bpm 
<65 bpm 65 ≤ HR ≤ 75 bpm >75 bpm 
A
B
(ml/mm Hg)
(mm Hg/ml)
Figure 2 Arterial Compliance and Elastance Graphs
(A) Total arterial compliance and heart rate subdivided in tertiles. (B) Effective
arterial elastance and heart rate (HR) subdivided in tertiles.
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1981Interestingly, CO was maintained in the ivabradine group
comparedwith the placebo group after 8months of treatment.Discussion
The inﬂuence of HR on afterload burden was investigated
in a cohort of patients with systolic HF. Isolated HR
reduction with ivabradine signiﬁcantly reduced Ea, a
parameter representing the pulsatile and mean load of the
left ventricle. This reduction of total afterload is mainly
triggered by a decrease in vascular pulsatile load indicated
by increased TAC, whereas systemic vascular resistance
remained constant. Improved TAC resulted in improved
ventricular-arterial coupling with a signiﬁcant increase in SV
without changes in LV contractility and CO.
HR and vascular function. The mutual interaction of HR
and Ea has been demonstrated experimentally in isolated
canine hearts at constant preload and impedance (12), and in
closed-chest dogs (17). In addition, this relation has been
seen in investigations in humans (8). Beside the study of
Maurer et al. (18) investigating the inﬂuence of carvedilol on
HR reduction and EF in heart failure with reduced ejectionfraction patients, this is the only study in which HR
dependency of Ea was investigated in the setting of long-
term treatment of humans. The apparent improvement in
TAC in this study is consistent with experimental and other
clinical data. In rats, increases in HR produced by atrial
pacing have been associated with a marked decrease in carotid
artery compliance (19). Similarly, HR has been directly
related to arterial stiffness in the central and lower limb
arteries (20) as well as in radial and carotid arteries of humans
(21). Interestingly, isolated HR reduction by ivabradine was
found to mediate antihypertrophic effects in the thoracic
aorta of rats as measured by a reduction of media cross-
sectional area; this alteration, in turn, reduced vascular wall
stress (22). Also, it has been shown experimentally that iso-
lated HR reduction with ivabradine improves aortic disten-
sibility by reducing aortic ﬁbrosis and oxidative stress (10).
However, in contrast to long-term treatment, acute short-
term repetitive intravenous administration of ivabradine did
not affect arterial stiffness (23). These ﬁndings suggest that
blood vessels can adapt to increased mechanical wall stress by
changing their tissue structure, elastic properties, and
geometry, possibly beneﬁcially inﬂuenced by HR reduction.
HR reduction and ventricular-arterial interaction. Ven-
tricular systolic and diastolic function as well as vascular tone
and compliance determine blood pressure and peripheral
ﬂow (13,24,25). In the PV relationship, ventricular systolic
performance is understood to be represented by the Ees,
whereas arterial function and afterload are characterized
by Ea (8,12). The coupling ratio Ea/Ees was introduced
to describe and evaluate ventricular-arterial interaction
(13,25,26). Ees and Ea are matched in healthy persons to
provide optimal transition of SV to the peripheral circula-
tion. Experimentally, the speciﬁc margin of the coupling
ratio Ea/Ees was 0.6 to 1.2 when work and efﬁciency of
myocardial function were optimal (27).
Ea and Ees increase with aging in both men and women
(28). Compared with the corresponding values of healthy
individuals 60 years of age (28,29), measured parameters of
the investigated patients were typical of the values found in
systolic HF (Table 3). These patients demonstrated
a rightward shift in the PV loop due to increased EDV and
Ea, whereas Ees considerably decreased compared with
healthy matched individuals (Fig. 4). The latter parameters
resulted in an abnormally high coupling ratio (24,25) leading
to decreased cardiac efﬁciency (30).
Similar to vasodilator therapy (15), HR reduction by
ivabradine reduced Ea, thereby improving ventricular-arterial
interaction. Due to a ﬂat Ees curve in the PV relationship of
patients with systolic HF (Fig. 4), reduction of Ea is accom-
panied by a relative increase in SV, whereas end-systolic blood
pressure remains nearly unchanged (15,25). However, no
signiﬁcant changes in Ees values (LV contractility) were
demonstrated between the groups. These results agree with
experimental studies reporting that LV contractility was not
inﬂuenced by ivabradine (31), except in high concentrations
(32) far beyond what might be achieved clinically.
Table 3
Inﬂuence of Selective Heart Rate Reduction With Ivabradine on
Hemodynamic Parameters After 8 Months of Treatment Compared With Placebo
Parameter
Ivabradine
(n ¼ 143)
Placebo
(n ¼ 132) p Value
Heart rate, beats/min
At baseline 71  12 71  11.0 0.71
At 8 months 60  10 68  12 <0.0001
Change from baseline to 8 months 11  13 2  12 <0.0001
p Value vs. baseline <0.0001 0.015
Pulse pressure, mm Hg
At baseline 47  12 45  11 0.28
At 8 months 49  14 48  13 0.51
Change from baseline to 8 months 2  13 3  11 0.75
p Value vs. baseline 0.03 0.005
End-systolic pressure, mm Hg
At baseline 111  14 109  13 0.33
At 8 months 113  15 112  14 0.56
Change from baseline to 8 months 2  14 3  13 0.72
p Value vs. baseline 0.04 0.006
MAP, mm Hg
At baseline 91.6  10.3 90.8  9.1 0.51
At 8 months 92.8  10.5 92.4  10.4 0.73
Change from baseline to 8 months 1.2  10.7 1.5  10.3 0.80
p Value vs. baseline 0.18 0.09
Stroke volume, ml
At baseline 59  16 59  16 0.80
At 8 months 67  16 58  16 <0.0001
Change from baseline to 8 months 9  17 1  16 <0.0001
p Value vs. baseline <0.0001 0.39
Total arterial compliance, ml/mm Hg
At baseline 1.35  0.53 1.38  0.48 0.62
At 8 months 1.49  0.58 1.30  0.51 0.004
Change from baseline to 8 months 0.14  0.59 0.08  0.48 <0.001
p Value vs. baseline 0.005 0.06
Effective arterial elastance, mm Hg/ml
At baseline 2.04  0.69 1.96  0.55 0.29
At 8 months 1.78  0.54 2.06  0.59 <0.0001
Change from baseline to 8 months 0.26  0.68 0.10  0.58 <0.0001
p Value vs. baseline <0.0001 0.04
Total peripheral resistance, mm Hg/ml
At baseline 0.02  0.01 0.02  0.01 0.59
At 8 months 0.02  0.01 0.03  0.01 0.53
Change from baseline to 8 months 0.00  0.01 0.00  0.01 0.27
p Value vs. baseline 0.18 0.001
Continued on the next page
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1982Adecrease in EDVwas identiﬁed in the ivabradine-treated
patients (Table 3). The decrease in EDVmight be induced by
improved ventricular-arterial coupling due to decreased Ea.
The leftward shift of the PV loop to smaller EDV values of
ivabradine-treated patients can be interpreted as reverse
remodeling (Fig. 4A).TheEa-elicited change is in accordance
with the data of the echocardiographic main study of the
SHIFT (5). Summing up, improved ventricular-arterial
interaction caused by HR reduction seems to contribute to
the increase in SV and improved cardiac efﬁciency, thereby
preserving CO of patients receiving ivabradine. Accordingly,
CO was maintained after acute intravenous administration
of ivabradine in patients with systolic HF (33).Study limitations. Blood pressure measurements of this
study were performed noninvasively by an arm cuff system.
Therefore, measurements could overestimate central blood
pressure in both groups because brachial artery pressure is
normally higher than aortic pressure due to central pressure
wave ampliﬁcation (34,35). Central blood pressure,
however, is also increased due to reﬂected pressure waves.
This increase is inﬂuenced by HR as well because lower
HRs improve synchronization of the forward and back-
ward traveling waves, resulting in higher central PPs (35).
Therefore, ivabradine-treated patients with HR reduction
of w10 beats/min may have had slightly higher central
systolic blood pressure levels compared with controls,
Table 3 Continued
Parameter
Ivabradine
(n ¼ 143)
Placebo
(n ¼ 132) p Value
Cardiac output, ml/min n ¼ 134 n ¼ 128
At baseline 4,091  1,029 4,123  1,074 0.80
At 8 months 3,992  978 3,868  979 0.30
Change from baseline to 8 months 100  1,159 254  1,006 0.24
p Value vs. baseline 0.31 <0.01
Calculation according to Sunagawa et al. (12)
End-systolic elastance, mm Hg/ml n ¼ 134 n ¼ 128
At baseline 1.08  0.58 1.13  0.64 0.45
At 8 months 1.30  0.71 1.20  0.67 0.25
Change from baseline to 8 months 0.22  0.46 0.07  0.43 0.005
p Value vs. baseline <0.0001 0.08
Effective arterial elastance/end-systolic
elastance
n ¼ 134 n ¼ 128
At baseline 2.43  1.55 2.34  1.55 0.65
At 8 months 1.80  1.09 2.30  1.44 0.002
Change from baseline to 8 months 0.63  1.30 0.04  1.21 <0.0001
p Value vs. baseline <0.0001 0.69
Ejection fraction n ¼ 134 n ¼ 128
At baseline 0.32  0.10 0.33  0.11 0.88
At 8 months 0.36  0.12 0.33  0.11 0.03
Change from baseline to 8 months 0.04  0.10 0.01  0.09 0.004
p Value vs. baseline <0.0001 0.41
End-systolic volume, ml n ¼ 143 n ¼ 132
At baseline 126.6  57.2 123.3  61 0.65
At 8 months 110.7  56.7 119.1  57 0.23
Change from baseline to 8 months 15.9  37.9 4.2  38.7 0.01
p-value vs. baseline <0.0001 0.23
End-diastolic volume, ml n ¼ 134 n ¼ 128
At baseline 181  62 176  65 0.51
At 8 months 167  59 172  62 0.46
Change from baseline to 8 months 15  40 4  42 0.04
p Value vs. baseline <0.0001 0.29
Relative change, % 5.9  20 0.7  24 0.01
Calculation according to Chen et al. (16)
End-systolic elastance, mm Hg/ml n ¼ 41 n ¼ 41
At baseline 1.36  0.44 1.43  0.45 0.47
At 8 months 1.32  0.49 1.36  0.45 0.74
Change from baseline to 8 months 0.03  0.44 0.07  0.43 0.69
p Value vs. baseline 0.6 0.3
V0, ml n ¼ 41 n ¼ 41
At baseline 37  51 57  68 0.14
At 8 months 12  56 38  55 0.04
Change from baseline to 8 months 25  47 19  54 0.61
p Value vs. baseline 0.002 0.03
Effective arterial elastance/end-systolic
elastance
n ¼ 41 n ¼ 41
At baseline 1.50  0.53 1.45  0.38 0.62
At 8 months 1.38  0.39 1.57  0.49 0.06
Change from baseline to 8 months 0.13  0.46 0.11  0.43 0.02
p Value vs. baseline 0.09 0.10
Values are mean  SD.
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measurement.
Because the Ees calculation according to Sunagawa et al.
(12) supposes an x-axis intercept of V0 ¼ 0 of ESPVR, Ees
was alternatively calculated according to Chen et al. (16) ina subgroup of 41 patients. The Chen et al. (16) calculation
was shown to be a reliable estimate of invasive measurements
assuming V0 s 0 (16). Conﬁrming the results of the
Sunagawa et al. Ees calculation, the Chen et al. technique
showed no signiﬁcant difference for Ees values within and
Volume (ml) 
Pressure
(mm Hg)
Scheme of the effects of ivabradine
in systolic heart failure 
0
0
25
50
75
100
50
 
100
 
150
 
200 
Ivabradine  8 months 
Ivabradine  baseline 
Non-failing
heart
Volume (ml) 
Pressure
(mm Hg)
Scheme of the effects of placebo
in systolic heart failure 
0
0
25
50
75
100
50 100
 
150
 
200 
Placebo  8 months 
Placebo  baseline 
Non-failing
heart
A
B
Figure 4 Schematic Pressure-Volume Loops
Schematic pressure-volume diagrams of the left ventricle in the ivabradine group
(red loops, A) and placebo (blue loops, B) at baseline (dotted blue or red loop)
and after 8 months of treatment (solid red or blue loop) compared with a non-
failing control (gray loop). Systolic heart failure is indicated by an increase in EDV,
ﬂat end-systolic elastance, reduced SV, and increased Ea in both groups (red and
blue dotted loop). Ivabradine treatment over 8 months reduced afterload (Ea),
thereby improving ventricular-arterial interaction with marked increase in SV
compared with placebo (red solid loop). Contractility indicated by Ees (Chen
calculation) in the ivabradine group (red ascending lines) did not differ signiﬁcantly
compared with that of the placebo group (blue ascending lines). Noticeable is the
prominent leftward shift of the x-axis intercept of ESPVR of the ivabradine group
(solid vs. dotted lines) indicating reverse remodeling. Placebo treatment did not
alter afterload, resulting in approximately congruent loops (blue dotted and solid
loop). Abbreviations as in Figure 1.
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Figure 3 Correlation Curves
(A) Scatterplot for the correlation between EF and Ea/Ees. (B) Scatterplot for the
correlation between DEF and DEa/Ees. Abbreviations as in Figure 1.
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1984between both groups. The x-axis intersection V0 of
ivabradine-treated patients, however, was signiﬁcantly shif-
ted to the left compared with the placebo group. The left-
ward shift of ESPVR can be interpreted as reverse
remodeling, whereas contractility (Ees) remained nearly
unchanged. This shift might also explain the inherent
disparity between Ees change in both calculations after
ivabradine treatment (Sunagawa Ees increased, Chen Ees
decreased by trend). The Sunagawa Ees steepened within
the ivabradine group more than that in the placebo group
after 8 months of treatment because the Sunagawa et al. Ees
does not account for V0, whereas V0 of the Chen calculation
decreased consistent with reverse remodeling. Therefore, the
measured increase in Ees (Sunagawa) in the ivabradine-
treated patients (Table 3) does not reﬂect actual increasein contractility but depends on the deﬁned mathematical
speciﬁcation.
In this study, no direct and therefore no invasive measures
of vascular structure and function were performed but should
be done in the future to conﬁrm the presented results.
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1985Conclusions
HR modulates cardiac afterload in chronic systolic HF, as
indicated by the alterations of Ea demonstrated in patients
from the SHIFT. Selective HR reduction with ivabradine
improved TAC, thus reducing Ea with improvement of
ventricular-arterial coupling. Because Ees, a marker of LV
contractility, remained unchanged, increased ventricular-
arterial coupling must be assumed to have produced the
increased SV seen in ivabradine-treated patients. Therefore,
unloading of the heart has been demonstrated as an
underlying hemodynamic mechanism of isolated HR
reduction and may contribute to the beneﬁcial outcome of
ivabradine-treated patients with systolic HF.
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